Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 135
Filtrar
1.
Cardiovasc Diabetol ; 23(1): 101, 2024 Mar 18.
Artigo em Inglês | MEDLINE | ID: mdl-38500162

RESUMO

BACKGROUND: The cumulative effect of postpartum weight retention from each pregnancy in a woman's life may contribute to her risk of ultimately developing type 2 diabetes and cardiovascular disease. However, there is limited direct evidence supporting this hypothesis. Thus, we sought to characterize the impact of postpartum weight retention on the trajectories of cardiovascular risk factors over the first 5-years after pregnancy. METHODS: In this prospective observational cohort study, 330 women (mean age 35.7 ± 4.3 years, mean pre-pregnancy body mass index 25.2 ± 4.8 kg/m2, 50.9% primiparous) underwent serial cardiometabolic characterization (anthropometry, blood pressure, lipids, oral glucose tolerance test, insulin sensitivity/resistance (Matsuda index, HOMA-IR), C-reactive protein (CRP), adiponectin) at 1-year, 3-years, and 5-years postpartum. Based on the magnitude of weight change between pre-pregnancy and 5-years postpartum, they were stratified into the following 3 groups: weight loss (n = 100), weight gain 0-6% (n = 110), and weight gain ≥ 6% (n = 120). RESULTS: At 1-year postpartum, cardiovascular risk factors did not differ between the groups. However, an adverse risk factor profile progressively emerged in the weight retention groups at 3- and 5-years. Indeed, after covariate adjustment, there was stepwise worsening (from the weight loss group to weight gain 0-6% to weight gain ≥ 6% group) of the following cardiovascular risk factors at 5-years: triglycerides (p = 0.001), HDL (p = 0.02), LDL (p = 0.01), apolipoprotein-B (p = 0.003), Matsuda index (p < 0.0001), HOMA-IR (p < 0.0001), fasting glucose (p = 0.07), and CRP (p = 0.01). Moreover, on logistic regression analyses, weight gain ≥ 6% emerged as an independent predictor of pre-diabetes/diabetes at 5-years (adjusted OR = 3.40, 95%CI: 1.63-7.09). CONCLUSION: Postpartum weight retention predicts trajectories of worsening cardiovascular risk factors and glucose intolerance over the first 5-years after delivery, consistent with its postulated contribution to future vascular disease in women.


Assuntos
Doenças Cardiovasculares , Diabetes Mellitus Tipo 2 , Diabetes Gestacional , Ganho de Peso na Gestação , Humanos , Gravidez , Feminino , Adulto , Fatores de Risco , Doenças Cardiovasculares/diagnóstico , Doenças Cardiovasculares/epidemiologia , Diabetes Mellitus Tipo 2/complicações , Estudos Prospectivos , Período Pós-Parto/fisiologia , Aumento de Peso , Redução de Peso , Fatores de Risco de Doenças Cardíacas , Proteína C-Reativa/metabolismo , Glicemia/metabolismo
2.
Diabetes Obes Metab ; 26(4): 1207-1215, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-38116699

RESUMO

AIM: The diagnosis of gestational diabetes (GDM) identifies women who are at future risk of developing type 2 diabetes. However, it is unclear if diagnosing GDM thus motivates women to increase physical activity after pregnancy or if this medicalization has the opposite effect of decreasing activity, possibly reflecting assumption of a sick role. We thus sought to evaluate the impact of diagnosing GDM on changes in maternal physical activity after pregnancy. METHODS: In this prospective cohort study, physical activity patterns were assessed by the Baecke questionnaire for the year before pregnancy and the first year postpartum in 405 white women comprising the following three gestational glucose tolerance groups: (a) those who did not have GDM (non-GDM; n = 247), (b) women with undiagnosed GDM (n = 46) and (c) those diagnosed with GDM (n = 112). RESULTS: In the year before pregnancy, mean adjusted total physical activity progressively decreased from non-GDM to undiagnosed GDM to diagnosed GDM (p = .067). Conversely, at 1 year postpartum, total physical activity was highest in those who had been diagnosed with GDM (p = .02). Compared with non-GDM, diagnosed GDM predicted an increase in total physical activity from pre-pregnancy to 1 year postpartum (t = 2.3, p = .02) whereas undiagnosed GDM predicted a concurrent decrease in leisure-time activity (t = -2.74, p = .006). Accordingly, the mean adjusted increase in body mass index from pre-pregnancy to 1 year postpartum was lowest in those with diagnosed GDM (0.26 ± 0.25 kg/m2 ), highest in undiagnosed GDM (1.23 ± 0.38 kg/m2 ) and intermediate in non-GDM (0.89 ± 0.22 kg/m2 ) (overall p = .04). CONCLUSION: Diagnosis of GDM leads to increased physical activity after pregnancy that may partially attenuate postpartum weight retention.


Assuntos
Diabetes Mellitus Tipo 2 , Diabetes Gestacional , Gravidez , Feminino , Humanos , Diabetes Gestacional/diagnóstico , Diabetes Mellitus Tipo 2/diagnóstico , Diabetes Mellitus Tipo 2/epidemiologia , Estudos Prospectivos , Período Pós-Parto , Exercício Físico
3.
Diabetologia ; 66(11): 2154-2163, 2023 11.
Artigo em Inglês | MEDLINE | ID: mdl-37612415

RESUMO

AIMS/HYPOTHESIS: Excess adiposity, insulin resistance and beta cell dysfunction each contribute to the development of prediabetes (impaired glucose tolerance and/or impaired fasting glucose)/diabetes but their comparative impact in relation to one another remains uncertain. We thus ranked their contributions to incident dysglycaemia over the first 5 years postpartum in women reflecting the full spectrum of gestational glucose tolerance (spanning normoglycaemia to gestational diabetes) and hence a range of future diabetic risk. METHODS: In this study, 302 women with normal glucose tolerance (NGT) on OGTT at 3 months postpartum underwent repeat OGTT at 1 year, 3 years and 5 years, enabling serial assessment of glucose tolerance, insulin sensitivity/resistance (Matsuda index, HOMA-IR) and beta cell function (insulin secretion-sensitivity index-2 [ISSI-2], insulinogenic index [IGI]/HOMA-IR). Determinants of prediabetes/diabetes were ranked by change in concordance index (CCI) of Cox proportional hazard regression models. RESULTS: Over 5 years of follow-up, 89 women progressed from NGT to prediabetes/diabetes (progressors). At 3 months postpartum, though all women were normoglycaemic, future progressors had higher fasting glucose (p=0.03) and 2 h glucose (p<0.0001) than non-progressors, coupled with higher BMI (p=0.001), greater insulin resistance (both Matsuda index and HOMA-IR, p≤0.02) and poorer beta cell function (both ISSI-2 and IGI/HOMA-IR, p≤0.006). Unlike their peers, progressors exhibited deteriorating beta cell function from 1 year to 5 years (both p<0.0001). On regression analyses, the dominant determinants of progression to prediabetes/diabetes were time-varying ISSI-2 (change in CCI 25.2%) and IGI/HOMA-IR (13.0%), in contrast to time-varying Matsuda index (2.9%) and HOMA-IR (0.5%). Neither time-varying BMI nor waist were significant predictors after adjustment for beta cell function and insulin sensitivity/resistance. CONCLUSION/INTERPRETATION: Declining beta cell function is the dominant determinant of incident prediabetes/diabetes in young women following pregnancy.


Assuntos
Diabetes Mellitus Tipo 2 , Resistência à Insulina , Células Secretoras de Insulina , Estado Pré-Diabético , Gravidez , Humanos , Feminino , Glucose , Glicemia/análise , Teste de Tolerância a Glucose , Células Secretoras de Insulina/fisiologia , Insulina
4.
BMC Pregnancy Childbirth ; 22(1): 119, 2022 Feb 11.
Artigo em Inglês | MEDLINE | ID: mdl-35148698

RESUMO

BACKGROUND: The provision of care to pregnant persons and neonates must continue through pandemics. To maintain quality of care, while minimizing physical contact during the Severe Acute Respiratory Syndrome-related Coronavirus-2 (SARS-CoV2) pandemic, hospitals and international organizations issued recommendations on maternity and neonatal care delivery and restructuring of clinical and academic services. Early in the pandemic, recommendations relied on expert opinion, and offered a one-size-fits-all set of guidelines. Our aim was to examine these recommendations and provide the rationale and context to guide clinicians, administrators, educators, and researchers, on how to adapt maternity and neonatal services during the pandemic, regardless of jurisdiction. METHOD: Our initial database search used Medical subject headings and free-text search terms related to coronavirus infections, pregnancy and neonatology, and summarized relevant recommendations from international society guidelines. Subsequent targeted searches to December 30, 2020, included relevant publications in general medical and obstetric journals, and updated society recommendations. RESULTS: We identified 846 titles and abstracts, of which 105 English-language publications fulfilled eligibility criteria and were included in our study. A multidisciplinary team representing clinicians from various disciplines, academics, administrators and training program directors critically appraised the literature to collate recommendations by multiple jurisdictions, including a quaternary care Canadian hospital, to provide context and rationale for viable options. INTERPRETATION: There are different schools of thought regarding effective practices in obstetric and neonatal services. Our critical review presents the rationale to effectively modify services, based on the phase of the pandemic, the prevalence of infection in the population, and resource availability.


Assuntos
COVID-19/prevenção & controle , Controle de Doenças Transmissíveis/organização & administração , Atenção à Saúde/organização & administração , Serviços de Saúde Materno-Infantil/organização & administração , Assistência Perinatal , Guias de Prática Clínica como Assunto , Complicações Infecciosas na Gravidez/prevenção & controle , Centros Médicos Acadêmicos , COVID-19/terapia , Canadá , Feminino , Humanos , Lactente , Recém-Nascido , Pacientes Internados , Política Organizacional , Pacientes Ambulatoriais , Gravidez , Complicações Infecciosas na Gravidez/terapia , SARS-CoV-2
5.
Can J Neurol Sci ; 48(6): 767-771, 2021 11.
Artigo em Inglês | MEDLINE | ID: mdl-33431076

RESUMO

BACKGROUND: Myasthenia gravis (MG) is an autoimmune disorder that frequently affects young women of reproductive age. The multidirectional interplay between MG, pregnancy, and fetal health poses a complex scenario for pregnant women with MG and the healthcare team. Here, we reviewed our local experience with MG, pregnancy, and outcomes. METHODS: We performed a retrospective chart review of patients with MG attending the Prosserman Family Neuromuscular Clinic from 2001 to 2019 and who were referred to a high-risk pregnancy clinic. MG status was defined as stable, better, or worse. Information was collected on the delivery route, pregnancy, and neonatal complications. RESULTS: We identified 20 women with MG for a total of 28 pregnancies. Worsening was observed in 50% of pregnancies: 18% during pregnancy, 25% following delivery, and 7% during both. 66.7% of patients with MG duration of 2 years or less had worsening during pregnancy. Three patients who stopped immunosuppressive treatment during pregnancy worsened and one had a crisis. C-section was done in 29% of pregnancies. The rate of delivery complications was 7% and of neonatal MG was 7%. CONCLUSION: A high proportion of MG patients worsened during pregnancy, particularly those with disease duration less than 2 years, and those who discontinued immunosuppression during pregnancy. However, pregnancy was largely unaffected, rate of neonatal MG was low, frequencies of C-section, delivery complications, and premature births were similar to the general population. While the study has limitations due to the retrospective nature, these insights provide some guidance when counseling young myasthenic women about family planning.


Assuntos
Miastenia Gravis , Complicações na Gravidez , Feminino , Humanos , Recém-Nascido , Miastenia Gravis/terapia , Gravidez , Complicações na Gravidez/epidemiologia , Complicações na Gravidez/terapia , Estudos Retrospectivos
6.
Arterioscler Thromb Vasc Biol ; 39(10): 2192-2197, 2019 10.
Artigo em Inglês | MEDLINE | ID: mdl-31412738

RESUMO

OBJECTIVE: apoA1 (apolipoprotein A-1) is the main lipoprotein associated with HDL (high-density lipoprotein) cholesterol. It was recently reported that intravenous infusion of apoA1 could lower insulin resistance in pregnant rats, leading to the suggestion that apoA1 could provide a target for reducing pregnancy-induced insulin resistance and the risk of gestational diabetes mellitus (GDM) in humans. However, the effects of apoA1 on insulin resistance and risk of GDM in human pregnancy are not known. Thus, we sought to systematically evaluate the relationships of apoA1 with glucose homeostasis and metabolic function in pregnant women. Approach and Results: In this study, 870 pregnant women were recruited in late second trimester and underwent metabolic characterization, including an oral glucose tolerance test on which 214 were diagnosed with GDM. Metabolic characterization included assessment of glucose tolerance, insulin sensitivity/resistance (Matsuda index, homeostasis model assessment of insulin resistance), pancreatic ß-cell function, lipids (LDL [low-density lipoprotein] cholesterol, HDL cholesterol, triglycerides, apoB [apolipoprotein B], and apoA1), CRP (C-reactive protein), and adiponectin. Serum apoA1 was strongly correlated with HDL (r=0.79, P<0.0001) and weakly so with adiponectin (r=0.12, P=0.0004) but showed no association with measures of insulin sensitivity/resistance, ß-cell function, glycemia, or CRP. There were no significant differences across apoA1 tertiles in mean adjusted Matsuda index (P=0.24), homeostasis model assessment of insulin resistance (P=0.08), or area under the glucose curve on the oral glucose tolerance test (P=0.96). Moreover, there were no differences in risk of GDM across tertiles of apoA1, both before (P=0.67) and after covariate adjustment (P=0.78). CONCLUSIONS: Serum apoA1 is not associated with insulin resistance or the risk of GDM in human pregnancy.


Assuntos
Apolipoproteína A-I/sangue , Glicemia/análise , Diabetes Gestacional/fisiopatologia , Resistência à Insulina/fisiologia , Resultado da Gravidez , Adiponectina/metabolismo , Adulto , Área Sob a Curva , Biomarcadores/sangue , Estudos de Coortes , Diabetes Gestacional/sangue , Feminino , Teste de Tolerância a Glucose , Humanos , Gravidez , Segundo Trimestre da Gravidez , Medição de Risco , Índice de Gravidade de Doença
7.
J Obstet Gynaecol Can ; 41(12): 1814-1825.e1, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-31785800

RESUMO

OBJECTIVES: This guideline reviews the evidence relating to the diagnosis and obstetrical management of diabetes in pregnancy. OUTCOMES: The outcomes evaluated were short and long-term maternal outcomes including pre-eclampsia, Caesarean section, future diabetes and other cardiovascular complications; and fetal outcomes including congenital anomalies, stillbirth, macrosomia, birth trauma, hypoglycemia and long-term effects. EVIDENCE: Published literature was retrieved through searches of PubMed and The Cochrane Library using appropriate controlled vocabulary (MeSH terms "diabetes" and "pregnancy"). Where appropriate, results were restricted to systematic reviews, randomized control trials/controlled clinical trials, and observational studies. There were no date limits but results were limited to English or French language materials. VALUES: The quality of evidence was rated using the criteria described in the Report of the Canadian Task Force on Preventive Health Care. SUMMARY STATEMENTS: RECOMMENDATIONS.


Assuntos
Diabetes Gestacional/terapia , Gravidez em Diabéticas/terapia , Diabetes Gestacional/diagnóstico , Feminino , Humanos , Programas de Rastreamento , Mortalidade Perinatal , Gravidez , Gravidez em Diabéticas/diagnóstico
8.
J Obstet Gynaecol Can ; 41(12): 1826-1839.e1, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-31785801

RESUMO

OBJECTIF: La présente Directive passe en revue les données probantes liées au diagnostic et à la prise en charge obstétricale du diabète durant la grossesse. ISSUES: Les issues évaluées étaient les issues maternelles à court et à long terme, dont la prééclampsie, la césarienne, le diabète éventuel et d'autres complications cardiovasculaires et les issues fœtales, dont les anomalies congénitales, la mortinaissance, la macrosomie, le traumatisme de la naissance, l'hypoglycémie et les effets à long terme. RéSULTATS: La littérature publiée a été récupérée par l'intermédiaire de recherches menées dans PubMed et The Cochrane Library au moyen d'un vocabulaire contrôlé (termes MeSH « diabète ¼ et « grossesse ¼) approprié. Le cas échéant, les résultats ont été restreints aux analyses systématiques, aux essais comparatifs randomisés / essais cliniques comparatifs et aux études observationnelles. Aucune limite n'a été imposée en matière de date, mais les résultats ont été limités aux articles publiés en anglais ou en français. VALEURS: La qualité des résultats a été évaluée au moyen des critères décrits dans le rapport du Groupe d'étude canadien sur les soins de santé préventifs. DÉCLARATIONS SOMMAIRES: RECOMMANDATIONS.

9.
Diabetologia ; 61(12): 2633-2642, 2018 12.
Artigo em Inglês | MEDLINE | ID: mdl-30112689

RESUMO

AIMS/HYPOTHESIS: The prevalence of gestational diabetes (GDM) is higher in summer months, possibly reflecting an association between ambient temperature and blood glucose levels. However, the specific exposure and mechanism by which temperature may affect glucose metabolism in pregnancy remains unclear. We systematically evaluated the relationships of environmental temperature and changes therein over varying durations of exposure time with beta cell function, insulin sensitivity and glucose tolerance in women undergoing antepartum screening for GDM. METHODS: At a mean gestation of 29 weeks, 1464 women in Toronto (ON, Canada) underwent an OGTT, from which 318 were diagnosed with GDM. Blood glucose, beta cell function and insulin sensitivity were evaluated in relation to 18 temperature variables: mean temperature and change in temperature on the day of the OGTT and over the preceding 7, 14, 21, 28, 35, 42, 49 and 56 days, respectively. RESULTS: Temperature changes in the preceding 14, 21, 28, 35, 42, 49 and 56 days (rather than mean temperatures) emerged as independent predictors of blood glucose. These relationships were evident in months where mean daily temperature was rising (February - July), but not in those where it was falling (August - January). Indeed, in February - July, the temperature changes in the preceding 21, 28 and 35 days emerged as predictors of both poorer beta cell function and higher blood glucose. Moreover, in February - July, the changes in temperature in the preceding 21 days (OR 1.16, 95% CI 1.01, 1.33) and 28 days (OR 1.20, 95% CI 1.03, 1.39) were independent predictors of GDM, while mean temperatures were not. CONCLUSIONS/INTERPRETATION: In pregnant women, rising environmental temperature in the 3-4 weeks prior to glucose tolerance testing may be associated with beta cell dysfunction and an increased risk of GDM.


Assuntos
Diabetes Gestacional/metabolismo , Células Secretoras de Insulina/metabolismo , Glicemia/metabolismo , Feminino , Humanos , Resistência à Insulina/fisiologia , Gravidez , Fatores de Risco , Temperatura
10.
Clin Endocrinol (Oxf) ; 88(2): 227-233, 2018 02.
Artigo em Inglês | MEDLINE | ID: mdl-29112786

RESUMO

CONTEXT: Circulating B-type natriuretic peptide, as measured by the N-terminal fragment of its prohormone (NT-proBNP), is inversely associated with incident type 2 diabetes (T2DM) but positively related to future cardiovascular disease (CVD). Recognizing that gestational diabetes (GDM) identifies women at future risk for both T2DM and CVD, we sought to determine whether gestational glucose tolerance relates to NT-proBNP in the years after delivery. DESIGN/PATIENTS/MEASUREMENTS: Three hundred and forty women underwent a glucose challenge test (GCT) and an oral glucose tolerance test (OGTT) in pregnancy, yielding 4 gestational glucose tolerance groups: GDM (n = 105); gestational impaired glucose tolerance (n = 59); abnormal GCT with a normal OGTT (n = 98); and normal GCT with normal OGTT (n = 75). At 3-year postpartum, they underwent cardiometabolic characterization (including measurement of estimated glomerular filtration rate (eGFR), adiponectin and NT-proBNP) and repeated the OGTT, revealing 69 women with glucose intolerance (prediabetes/diabetes). RESULTS: At 3-year postpartum, serum NT-proBNP did not differ between the 4 original gestational glucose tolerance groups (P = .44), but instead progressively decreased across current glucose tolerance strata, from normal to prediabetes to diabetes (P = .006). Indeed, on logistic regression analysis, NT-proBNP emerged as a negative predictor of prediabetes/diabetes (OR = 0.903, 95% CI 0.825-0.988, P = .026). On multiple linear regression analyses of NT-proBNP, the significant association with current glucose intolerance was ultimately attenuated in a fully adjusted model, revealing two independent determinants of NT-proBNP: eGFR (t = -2.71, P = .007) and adiponectin (t = 2.44, P = .015). CONCLUSION: Serum NT-proBNP relates to current glucose intolerance, rather than preceding gestational dysglycaemia. Thus, the diabetic (rather than vascular) risk implications of NT-proBNP predominate in young women.


Assuntos
Diabetes Gestacional/sangue , Intolerância à Glucose/sangue , Peptídeo Natriurético Encefálico/sangue , Adulto , Glicemia/metabolismo , Diabetes Gestacional/fisiopatologia , Feminino , Intolerância à Glucose/fisiopatologia , Teste de Tolerância a Glucose , Humanos , Fragmentos de Peptídeos/sangue , Período Pós-Parto/sangue , Gravidez , Estudos Prospectivos
12.
J Obstet Gynaecol Can ; 40(5): 566-571, 2018 05.
Artigo em Inglês | MEDLINE | ID: mdl-29153738

RESUMO

OBJECTIVE: This study sought to report pregnancy outcomes in women following cardiac transplantation. METHODS: This was a descriptive retrospective cohort study of women with pregnancies following cardiac transplantation managed at two large tertiary centres in Canada and Belgium between 2001 and 2017. RESULTS: Sixteen women had 17 singleton pregnancies following cardiac transplantation. The mean maternal age was 28 ± 5.8, and the transplant-to-pregnancy interval was 7.3 ± 4.0 years. There were two first trimester terminations, one for teratogenicity concerns and the other because of a maternal cardiac condition. There was one spontaneous miscarriage. All women had normal left ventricular function at the start of pregnancy. Graft rejection occurred in two women. Other maternal complications included anemia requiring blood transfusion (n = 5), renal failure or deterioration (n = 4), preeclampsia (n = 2), and urine infections (n = 2). The mean GA at delivery was 35 ± 3.5 weeks. Six infants were born preterm, and two were small-for-gestational-age. Fetal anomalies were identified in two pregnancies. Women were followed after pregnancy for a median of 5.6 years (range, 10 months to 15 years). Although there were no deaths during pregnancy, two women died at 10 and 18 months after delivery. CONCLUSION: With appropriate multidisciplinary care, women with cardiac transplants can have successful pregnancies. Although rates of fetal loss are low, these women continue to be at risk for graft rejection, preterm birth, other pregnancy-related complications, and cardiovascular death.


Assuntos
Transplante de Coração , Complicações na Gravidez/epidemiologia , Resultado da Gravidez/epidemiologia , Adulto , Feminino , Transplante de Coração/mortalidade , Transplante de Coração/estatística & dados numéricos , Humanos , Recém-Nascido , Recém-Nascido Pequeno para a Idade Gestacional , Gravidez , Nascimento Prematuro , Estudos Retrospectivos , Adulto Jovem
13.
Eur Heart J ; 38(19): 1509-1516, 2017 May 14.
Artigo em Inglês | MEDLINE | ID: mdl-28329059

RESUMO

AIMS: To review maternal and foetal outcomes in women with mechanical heart valves (MHVs) treated with vitamin-K antagonists (VKAs), first-trimester heparin followed by VKAs (sequential treatment), low molecular weight heparin (LMWH) and unfractionated heparin (UFH) during pregnancy, in order to inform practice. METHODS AND RESULTS: Medline, Embase and Central were searched from inception until February 2016. Two reviewers independently screened 1786 titles, reviewed 110 full-texts and extracted data and assessed risk-of-bias from 46 articles. Pooled incidence (95% confidence intervals) was calculated for maternal and foetal outcomes. Included studies had a moderate or high risk-of-bias. With VKAs, sequential treatment and LMWH, maternal mortality occurred in 0.9% (0.4-1.4), 2.0% (0.8-3.1) and 2.9% (0.2-5.7), thromboembolic complications in 2.7% (1.4-4.0), 5.8% (3.8-7.7) and 8.7% (3.9-13.4), livebirths in 64.5% (48.8-80.2), 79.9% (74.3-85.6) and 92.0% (86.1-98.0) and anticoagulant-related foetal/neonatal adverse events (embryopathy or foetopathy) in 2.0% (0.3-3.7), 1.4% (0.3-2.5) and 0%, respectively. When UFH is used throughout pregnancy, 11.2% (2.8-19.6) suffered thromboembolic complications. Foetal loss and adverse events occurred with first-trimester warfarin doses ≤ 5 mg/day, although there were more livebirths [83.6% (75.8-91.4) vs. 43.9% (32.8-55.0)] and fewer foetal anomalies [2.3% (0.7-4.0) vs. 12.4% (3.3-21.6)] with lower doses than with warfarin > 5 mg/day. CONCLUSIONS: VKAs are associated with fewest maternal complications but also with fewest livebirths. Sequential treatment does not eliminate anticoagulant-related foetal/neonatal adverse events. LMWH is associated with the highest number of livebirths. The safety of UFH throughout pregnancy and first-trimester warfarin ≤ 5 mg/day remains unconfirmed.


Assuntos
Anticoagulantes/efeitos adversos , Próteses Valvulares Cardíacas , Complicações Cardiovasculares na Gravidez/terapia , Feminino , Morte Fetal/etiologia , Doenças Fetais/induzido quimicamente , Heparina/efeitos adversos , Heparina de Baixo Peso Molecular/efeitos adversos , Humanos , Incidência , Mortalidade Materna , Gravidez , Resultado da Gravidez , Primeiro Trimestre da Gravidez , Tromboembolia/prevenção & controle , Vitamina K/antagonistas & inibidores , Varfarina/efeitos adversos
14.
Am J Physiol Endocrinol Metab ; 312(3): E215-E223, 2017 03 01.
Artigo em Inglês | MEDLINE | ID: mdl-27965206

RESUMO

Breastfeeding for ≥12 mo is recommended for optimal infant nutrition but may hold maternal benefits as well. Indeed, lactation has been associated with lower long-term risk of diabetes in the mother, but the mechanism by which it imparts sustained postweaning effects on glucose tolerance remains unclear. In this context, we postulated that lactation could potentially induce postweaning beneficial effects on glucose tolerance by modifying the natural history of insulin sensitivity and/or pancreatic ß-cell function over time. Thus, in this study, we evaluated the relationships between duration of lactation [≤3 mo (n = 70), 3-12 mo (n = 140), and ≥12 mo (n = 120)] and trajectories of insulin sensitivity/resistance, ß-cell function, and glycemia over the first 3 yr postpartum in a cohort of 330 women comprising the full spectrum of glucose tolerance in pregnancy, who underwent serial metabolic characterization, including oral glucose tolerance tests, at 3 mo, 1 yr, and 3 yr postpartum. The prevalence of dysglycemia (pre-diabetes/diabetes) at 3 yr postpartum was lower in women who breastfed for ≥12 mo (12.5%) than in those who breastfed for ≤3 mo (21.4%) or for 3-12 mo (25.7%)(overall P = 0.028). On logistic regression analysis, lactation for ≥12 mo independently predicted a lower likelihood of prediabetes/diabetes at 3 yr postpartum (OR = 0.37, 95% CI 0.18-0.78, P = 0.009). Notably, lactation for ≥12 mo predicted lesser worsening of insulin sensitivity/resistance (P < 0.0001), fasting glucose (P < 0.0001), and 2-h glucose (P = 0.011) over 3 yr compared with lactation ≤3 mo but no differences in ß-cell function (P ≥ 0.37). It has thus emerged that adherence to current breastfeeding recommendations reduces future diabetic risk through sustained postweaning effects on insulin sensitivity/resistance but not ß-cell function.


Assuntos
Aleitamento Materno/estatística & dados numéricos , Diabetes Mellitus Tipo 2/epidemiologia , Diabetes Gestacional/epidemiologia , Intolerância à Glucose/epidemiologia , Resistência à Insulina , Lactação , Estado Pré-Diabético/epidemiologia , Adulto , Glicemia/metabolismo , Estudos de Coortes , Diabetes Mellitus Tipo 2/metabolismo , Diabetes Gestacional/metabolismo , Jejum , Feminino , Intolerância à Glucose/metabolismo , Teste de Tolerância a Glucose , Humanos , Células Secretoras de Insulina/metabolismo , Modelos Lineares , Modelos Logísticos , Estado Pré-Diabético/metabolismo , Gravidez , Estudos Prospectivos , Risco , Fatores de Tempo
15.
J Obstet Gynaecol Can ; 39(8): e121-e129, 2017 Aug.
Artigo em Francês | MEDLINE | ID: mdl-28729103

RESUMO

OBJECTIF: Le présent document résume notre expérience limitée quant à la présence du SRAS pendant la grossesse et suggère des lignes directrices quant à sa prise en charge. ISSUES: Les exposés de cas issus d'Asie laissent entendre que les issues maternelles et fœtales sont aggravées par la présence du SRAS pendant la grossesse. RéSULTATS: Des recherches ont été menées dans Medline afin d'en tirer les articles pertinents publiés en anglais entre 2000 et 2007. Des exposés de cas ont été analysés et nous avons sollicité l'opinion de spécialistes. VALEURS: Les recommandations ont été formulées conformément aux lignes directrices élaborées par le Groupe d'étude canadien sur les soins de santé préventifs. COMMANDITAIRE: La Société des obstétriciens et gynécologues du Canada. RECOMMANDATIONS.

16.
J Obstet Gynaecol Can ; 39(8): e130-e137, 2017 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-28729104

RESUMO

OBJECTIVE: This document summarizes the limited experience of SARS in pregnancy and suggests guidelines for management. OUTCOMES: Cases reported from Asia suggest that maternal and fetal outcomes are worsened by SARS during pregnancy. EVIDENCE: Medline was searched for relevant articles published in English from 2000 to 2007. Case reports were reviewed and expert opinion sought. VALUES: Recommendations were made according to the guidelines developed by the Canadian Task Force on Preventive Health Care. SPONSORS: The Society of Obstetricians and Gynaecologists of Canada.


Assuntos
Assistência Perinatal/métodos , Complicações Infecciosas na Gravidez/terapia , Síndrome Respiratória Aguda Grave/terapia , Canadá , Feminino , Pessoal de Saúde/organização & administração , Humanos , Recém-Nascido , Controle de Infecções/métodos , Isolamento de Pacientes/métodos , Gravidez
17.
Cardiol Young ; 27(8): 1529-1537, 2017 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-28412993

RESUMO

OBJECTIVES: Individuals with childhood-onset coronary artery anomalies are at increased risk of lifelong complications. Although pregnancy is thought to confer additional risk, a few data are available regarding outcomes in this group of women. We sought to define outcomes of pregnancy in this unique population. METHODS: We performed a retrospective survey of women with paediatric-onset coronary anomalies and pregnancy in our institution, combined with a systematic review of published cases. We defined paediatric-onset coronary artery anomalies as congenital coronary anomalies and inflammatory arteriopathies of childhood that cause coronary aneurysms. Major cardiovascular events were defined as pulmonary oedema, sustained arrhythmia requiring treatment, stroke, myocardial infarction, cardiac arrest, or death. RESULTS: A total of 25 surveys were mailed, and 20 were returned (80% response rate). We included 46 articles from the literature, which described cardiovascular outcomes in 82 women (138 pregnancies). These data were amalgamated for a total of 102 women and 194 pregnancies; 59% of women were known to have paediatric-onset coronary artery anomalies before pregnancy. In 23%, the anomaly was unmasked during or shortly after pregnancy. The remainder, 18%, was diagnosed later in life. Major cardiovascular events occurred in 14 women (14%) and included heart failure (n=5, 5%), myocardial infarction (n=7, 7%), maternal death (n=2, 2%), cardiac arrest secondary to ventricular fibrillation (n=1, 1%), and stroke (n=1, 1%). The majority of maternal events (13/14, 93%) occurred in women with no previous diagnosis of coronary disease. CONCLUSIONS: Women with paediatric-onset coronary artery anomalies have a 14% risk of adverse cardiovascular events in pregnancy, indicating the need for careful assessment and close follow-up. Prospective, multicentre studies are required to better define risk and predictors of complications during pregnancy.


Assuntos
Anomalias dos Vasos Coronários , Complicações Cardiovasculares na Gravidez , Diagnóstico Pré-Natal/métodos , Anomalias dos Vasos Coronários/diagnóstico , Anomalias dos Vasos Coronários/epidemiologia , Anomalias dos Vasos Coronários/etiologia , Feminino , Saúde Global , Humanos , Incidência , Recém-Nascido , Gravidez
18.
Clin Endocrinol (Oxf) ; 84(5): 680-6, 2016 May.
Artigo em Inglês | MEDLINE | ID: mdl-26641010

RESUMO

BACKGROUND: Pregnancy and lactation comprise a critical window spanning all seasons during which maternal vitamin D status potentially may influence the long-term health of the newborn. Women typically receive calcium/vitamin D supplementation through antenatal vitamins, but there has been limited serial evaluation of maternal vitamin D status across this critical window. DESIGN/PATIENTS/MEASUREMENTS: In this prospective observational cohort study, 467 women in Toronto, Canada, underwent measurement of serum 25-hydroxy vitamin D (25-OH-D) at mean 29·7 ± 2·9 weeks' gestation, 3 months postpartum and 12 months postpartum, enabling serial assessment across 3 seasons. At each assessment, vitamin D status was classified as deficiency (25-OH-D<50 nmol/l), insufficiency (25-OH-D≥50 nmol/l and <75 nmol/l) or sufficiency (25-OH-D≥75 nmol/l). RESULTS: The prevalence rates of vitamin D deficiency and insufficiency were 31·5% and 35·1% in pregnancy, 33·4% and 35·3% at 3 months, and 35·6% and 33·8% at 12 months postpartum, respectively. These high rates remained stable over time (P = 0·49) despite declining usage of antenatal calcium/vitamin D supplementation from pregnancy to 3 months to 12 months postpartum (P < 0·001). Indeed, on mixed model analyses, vitamin D deficiency and insufficiency in pregnancy were independently associated with decrements in average 25-OH-D over time of 49·6 nmol/l and 26·4 nmol/l, respectively (both P < 0·001). In contrast, season of baseline assessment and use of calcium/vitamin D supplements were independently associated with changes in 25-OH-D in the range of 3-5 nmol/l (both P < 0·008). CONCLUSIONS: The persistence of vitamin D deficiency/insufficiency during pregnancy and lactation, irrespective of season and supplementation, supports the emerging concept that current vitamin D supplementation in antenatal care is likely inadequate.


Assuntos
Suplementos Nutricionais , Lactação/fisiologia , Complicações na Gravidez/fisiopatologia , Estações do Ano , Deficiência de Vitamina D/fisiopatologia , Vitamina D/administração & dosagem , Feminino , Seguimentos , Humanos , Lactente , Recém-Nascido , Modelos Lineares , Ontário/epidemiologia , Período Pós-Parto/fisiologia , Gravidez , Complicações na Gravidez/tratamento farmacológico , Complicações na Gravidez/epidemiologia , Prevalência , Estudos Prospectivos , Fatores de Tempo , Vitamina D/metabolismo , Deficiência de Vitamina D/tratamento farmacológico , Deficiência de Vitamina D/epidemiologia , Vitaminas/administração & dosagem , Vitaminas/metabolismo
19.
J Obstet Gynaecol Can ; 38(11): 1028-1032, 2016 11.
Artigo em Inglês | MEDLINE | ID: mdl-27969556

RESUMO

BACKGROUND: Thrombotic thrombocytopenic purpura (TTP) is a life-threatening illness that occurs in both pregnant and non-pregnant women. Several other conditions can mimic the disease, which makes the diagnosis challenging. CASE: We describe a case of severe Staphylococcus aureus endocarditis that initially presented as peripartum TTP in a 39-year-old woman at 29+6 weeks' gestation. We give an overview of the diagnostic considerations and management of thrombocytopenia in pregnancy and review the literature related to TTP and peripartum infective endocarditis. CONCLUSION: Given the significant differences in definitive therapies for the spectrum of thrombocytopenic conditions that occur in pregnancy, timely and accurate diagnosis of TTP is critical for optimal management.


Assuntos
Endocardite , Complicações Hematológicas na Gravidez , Complicações Infecciosas na Gravidez , Púrpura Trombocitopênica Trombótica , Infecções Estafilocócicas , Staphylococcus aureus , Adulto , Ecocardiografia Transesofagiana , Feminino , Humanos , Período Periparto , Gravidez , Valva Tricúspide/diagnóstico por imagem , Valva Tricúspide/patologia
20.
J Obstet Gynaecol Can ; 38(7): 667-679.e1, 2016 07.
Artigo em Inglês | MEDLINE | ID: mdl-27591352

RESUMO

OBJECTIVE: This guideline reviews the evidence relating to the diagnosis and obstetrical management of diabetes in pregnancy. OUTCOMES: The outcomes evaluated were short- and long-term maternal outcomes, including preeclampsia, Caesarean section, future diabetes, and other cardiovascular complications, and fetal outcomes, including congenital anomalies, stillbirth, macrosomia, birth trauma, hypoglycemia, and long-term effects. EVIDENCE: Published literature was retrieved through searches of PubMed and the Cochrane Library using appropriate controlled vocabulary (MeSH terms "diabetes" and "pregnancy"). Where appropriate, results were restricted to systematic reviews, randomized control trials/controlled clinical trials, and observational studies. There were no date limits, but results were limited to English or French language materials. VALUES: The quality of evidence was rated using the criteria described in the Report of the Canadian Task Force on Preventive Health Care (Table 1). SUMMARY STATEMENTS: Recommendations It is recognized that the use of different diagnostic thresholds for the "preferred" and "alternative" strategies could cause confusion in certain settings. Despite this, the committee has identified the importance of remaining aligned with the current Canadian Diabetes Association 2013 guidelines as being a priority. It is thus recommended that each care centre strategically align with 1 of the 2 strategies and implement protocols to ensure consistent and uniform reporting of test results.


Assuntos
Diabetes Gestacional , Gravidez em Diabéticas , Adulto , Glicemia , Aleitamento Materno , Canadá , Diabetes Mellitus , Diabetes Gestacional/diagnóstico , Diabetes Gestacional/terapia , Feminino , Humanos , Hiperglicemia/complicações , Gravidez , Gravidez em Diabéticas/diagnóstico , Gravidez em Diabéticas/terapia , Natimorto , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA